Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

Amneal Pharmaceuticals, Inc. today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group , for IPX203 in the European Union, United...

Related Keywords

Italy ,United States ,Canada ,Vicenza ,Veneto ,Switzerland ,Brazil ,France ,China ,Gibrat ,Midi Pyrées ,United Kingdom ,America ,Italian ,Frank Weber ,Chintu Patel ,Knight Therapeutics Inc ,Amneal Group ,Parkinson Foundation ,Amneal Pharmaceuticals Inc ,Young ,Exchange Commission ,Drug Administration ,Nasdaq ,European Union ,Amneal Pharmaceuticals ,Zambon Biotech ,Co Chief Executive Officers ,Chief Executive Officer ,Knight Therapeutics ,Breath Therapeutics ,Forward Looking Statements ,Securities Litigation Reform Act ,Common Stock ,Annual Report ,Young Onset Parkinson ,Markets ,